Media Thread, page-14166

Some of us are saying things along these lines...

...IMU should be more transparent and upfront about data and where we are at with trials, cause we have a world-beating cancer product. ...IMU should be promoting better, hooking in big investors in the US, cause we have a world beating cancer drug
...IMU should be talking up and about the commercial viability/markets available etc, cause we have a world beating cancer drug(perhaps not) World beating cancer productI suppose there is the possibility that we don't have a world beater cancer product (at least not yet).
CF33/Vaxxinia is just simply not at the stage of producing world beating data.

Roadblocks to getting an oncology drug to market. I have invested here and understand there is a big risk in this speculative stock, we all know this, but do we know how risky this is/what level are we talking about?

1. Oncology products are THE hardest to get to market (AFAIK), less than 5% get from pre-clinical to Ph3. Just, think about that - 95% never get there.

2. OV - is still relatively new (when it comes to being tested in people - not preclinically).
Who of us hasn't see the YF video about the vaccinia virus and the pre-clinical work, its great! + YF did say at a preso last year the virus is doing what we want/expect in humans (or something like that). Great, it sounds like its translating over! But the context is important, I think he meant it is infecting cancerous cells and replicating (and they could see that - through hNIS), this is good, but this is not the same as we can see that all cancers cells are dying/being destroyed. For ph 2 BP will only care about the results of SD and CR etc. We do know that pre-treated people with shot immune systems, will not respond as well to viruses (at elast through IV).

So just know that you/we are investing in an area where a. 95% fail and b. OV's we don't know how effective they will be in humans.

We wait on data
Are the products world beaters? Perhaps/perhaps not. I don't know, but I suppose we await the data in particular it seems data from Oncarlytics/Azer-cel and data from Phase 2, which means the window is either 2025 or even 2026. You can say IMU should be showing what great products we have, or has the upper hand, and we should get 100 millions of investment money. However the reality is that we are just not at that stage, and everything the company is doing currently speaks to this reality... after all they have...

1. Re-prioritised to Azer-Cell/Oncarlytics (thus never talk about other products-lately)
2. Shed the manufacturing plant - to get us through this year, what happens next year? Assuming/hoping/planning for Oncarlytics takes off - this is perhaps the last shot.
3. Say who knows why SP is down? (what is LC gonna say instead - we are down cause we cant commercialise our products/ or/ the data is good but you know, not great enough, no-one is interested?

so LC says data, data, data.

DYOR and all that, all of this is just thoughts/speculation etc.